When a company raises its outlook, it's telling the market business is running hotter than expected — and stocks often keep climbing in the weeks after that kind of surprise. Hims & Hers is doing exactly that even though its popular weight-loss drugs brin

Verdict: HIMS momentum idea is plausible, but the cash-flow slide says wait

The strongest point for this idea is real: Q2 revenue of $753.2M rose 23.9% sequentially and the August 14 Yahoo Finance piece frames a guidance raise as a fresh catalyst, exactly the pattern the idea wants. The strongest point against is equally concrete — free cash flow dropped 60.2% to $21.1M, gross margin slid from 65.2% to 63.8%, and the company posted two straight quarterly losses (-$92.1M, then -$86.3M) after a profitable fiscal 2025 with $128.4M of net income. Insiders were net open-market sellers of roughly $3.0M in the ownership filing covering the period ended June 30, 2026 — a delayed disclosure whose deadline has passed, not a current signal. On trade readiness, the entry is genuinely close: price at $31.86 sits $1.47 above the $30.39 50-day EMA and MACD at -0.48 is near flipping, but RSI at 60.6 is too high for the required fresh cross above 45, and the nearest resistance at $31.93 leaves almost no level-based room. Because HIMS daily market data could not be verified in the analysis window, the rule set carries no historical trade statistics — the decision rests on the live levels and the fundamentals. The verdict that fits the evidence is wait: let the MACD flip, the RSI reset, and the early-November filing (revenue versus $753.2M, gross margin versus 63.8%) confirm which side of the volume-versus-margin trade is winning.

Trade now

**HIMS closed Friday at $31.86**, and the long entry is close but not confirmed. The setup needs four things at once: price at or above the 50-day EMA (now at $30.39 — met, with price $1.47 above it), RSI (14) crossing above 45 (RSI sits at 60.6, so no fresh cross is in play), the MACD histogram turning positive (currently -0.48, the nearest condition to flipping), and the day's low touching the first support level at $31.00. In short: two conditions live, one near, one not — the trade is a **wait**, not a buy. **What 'wait' means concretely:** no position until the MACD histogram moves above zero and a fresh RSI cross above 45 prints alongside price holding the 50-day EMA. If you get filled, the rules set a 5% take-profit and a 2.5% stop on entry price, with a secondary target at the first resistance level ($31.93 — only ~0.2% above Friday's close, so effectively an immediate target) and a time-based exit after 60 daily bars. Risk sizing is 2.5% of capital per position, capped at 25% of the portfolio. **Reward:risk reality check.** With nearest resistance less than a quarter-percent above the last close, the level-based profit target offers almost no room; the 5% fixed take-profit is the meaningful upside leg, against a 2.5% fixed stop — roughly 2-to-1 if entry comes near $31.86. That's acceptable only if the momentum conditions actually align; chasing before the MACD flip risks buying a fakeout. One scope note: this rule set could not be backtested — market-data coverage could not be verified within the analysis retry window, and no parameter variants were searched — so the plan above rests on the live levels, not on historical trade statistics. The idea itself frames HIMS as a post-guidance momentum trade, not a buy-and-hold, and the numbers support that framing: Q2 revenue grew 23.9% sequentially to $753.2M, but gross margin slipped to 63.8% and free cash flow fell 60.2% quarter-over-quarter to $21.1M.

Guidance Is Up, and the Revenue Engine Is Delivering

The bull case rests on a simple trade the idea is explicitly making: volume over margin. The most recent quarter (period ending June 30, 2026) shows revenue of $753.2M, up 23.9% from $608.1M in the prior quarter. That is the kind of sequential acceleration that supports the raised outlook described in the August 14, 2026 Yahoo Finance piece, which framed the guidance raise as evidence the business is running hotter than expected. For a near-term momentum setup, a fresh guidance catalyst layered on accelerating top-line growth is the core bullish fact pattern. The full-year 2025 fundamentals show this company can convert scale into profits when the…

Scores

• Conviction score breakdown: 48
• Thesis support: 55
• Trade readiness: 50
• Risk quality: 45
• Fundamentals trend: 40

Watch items

• HIMS — MACD (12,26,9) histogram
• HIMS — RSI (14)
• HIMS — Price vs 50-day EMA
• HIMS — Daily low vs first support
• HIMS — Gross margin
• HIMS — Free cash flow (quarterly)
• HIMS — Insider net open-market activity
• HIMS — Quarterly revenue
• HIMS — Price
• HIMS — RSI (14) crossed above 45
• HIMS — MACD (12,26,9) above 0